HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Liver Neoplasms (Liver Cancer)

Subscribe to New Research on Liver Neoplasms

Tumors or cancer of the LIVER.

Also Known As:

Liver Cancer; Cancer of the Liver; Hepatic Neoplasms; Neoplasms, Hepatic; Neoplasms, Liver; Cancer, Hepatic; Cancer, Liver; Cancers, Hepatic; Cancers, Liver; Hepatic Cancers; Hepatic Neoplasm; Liver Cancers; Liver Neoplasm; Neoplasm, Hepatic; Neoplasm, Liver; Cancer of Liver; Hepatic Cancer

Networked: 6078 relevant articles (228 outcomes, 848 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Hepatocellular Carcinoma (Hepatoma)
3.	Neoplasm Metastasis (Metastasis)
4.	Fibrosis (Cirrhosis)
5.	Infection

Experts

1.	Calvisi, Diego F: 23 articles (03/2015 - 05/2003)
2.	Thorgeirsson, Snorri S: 21 articles (10/2015 - 02/2003)
3.	Lu, Shelly C: 19 articles (11/2015 - 04/2005)
4.	Kudo, Masatoshi: 18 articles (11/2015 - 01/2003)
5.	Groopman, John D: 17 articles (01/2015 - 08/2002)
6.	Liu, Jie: 15 articles (10/2015 - 06/2007)
7.	Li, Li: 15 articles (08/2015 - 07/2002)
8.	Llovet, Josep M: 15 articles (04/2015 - 03/2005)
9.	Wang, Jiayi: 15 articles (01/2015 - 03/2010)
10.	Mato, José M: 14 articles (11/2015 - 04/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Liver Neoplasms:

1.	sorafenib (BAY 43-9006)FDA Link 08/01/2010 - "There is a better efficacy of Nexavar in treatment of liver cancer in the patients who had Ki-67-positive expression and high MVD count." 10/01/2012 - "To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer. " 08/01/2010 - "The therapeutic efficacy of Nexavar on liver cancer was observed. " 08/01/2010 - "[Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34]." 01/01/2013 - "Improvements in patient stratification (for example, using the Barcelona Clinic Liver Cancer staging system) and the introduction of novel therapies (such as sorafenib) have improved patient survival. "
2.	Doxorubicin (Adriamycin)FDA LinkGeneric 11/01/1993 - "It has been used experimentally and clinically in the treatment of liver cancer to increase the efficacy of drugs such as doxorubicin. " 02/01/2009 - "Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer." 01/01/2013 - "The present study is designed to evaluate the effect of transcatheter intraarterial techniques on the distribution of doxorubicin in relation to blood vessels in liver cancer. " 02/01/2011 - "The purpose of this study was to investigate whether PARP-1 inhibition sensitizes human liver cancer cell lines to doxorubicin treatment. " 06/01/2010 - "The purpose of the present study was to evaluate the effect of BrTet on the sensitivity of doxorubicin (Dox) induced apoptosis in intrinsic resistant human hepatic cancer Bel7402 cells. "
3.	Ethiodized Oil (Ethiodol)FDA Link 03/01/2015 - "The newly synthesized (188)Re-HDD/lipiodol showed improved radiolabeling yield and biodistribution results compared to (188)Re-HTDD/lipiodol, and may therefore be more suitable for liver cancer therapy." 07/01/2010 - "Reported CR ratio of definitely hypervascular HCC are around 30-60% by superselective TACE with Lipiodol for hypervascular HCC less than 5 cm. According to a nationwide survey by the Liver Cancer Study Group of Japan (LCSGJ), overall 5-year survival rate was 26% in patients with HCCs not indicated for surgery or RFA (PEI), mainly treated by segmental or subsegmental TACE using Lipiodol. " 03/01/2008 - "The Nuclear Medicine Section of IAEA's Division of Human Health initiated the first Doctoral CRP of IAEA in the year 2000, entitled, "Management of Liver Cancer Using Radionuclide Methods with Special Emphasis on Trans-Arterial Radio-conjugate Therapy and Internal Dosimetry." Since then, the CRP has accomplished several milestones, including development of a new therapeutic radiopharmaceutical ((188)Re lipiodol) and successfully carrying out Phase I and Phase II clinical trials on patients using the new therapeutic radiopharmaceutical." 01/01/2007 - "A lipiodol solution of (188)Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol ((188)Re-HDD/lipiodol) is in clinical study for liver cancer therapy. " 03/01/2015 - "A lipiodol solution of (188)Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol (HTDD) has been successfully developed for liver cancer therapy; however, its preparation requires a multi-step synthesis and it is characterized by a low labeling yield. "
4.	Small Interfering RNA (siRNA)IBA 12/01/2013 - "It is also shown that siRNA-mediated silencing of SHH gene expression resulted in a significant reduction of cell proliferation in a liver cancer cell line, SNU449 indicating that SHH plays a major role in promoting cell proliferation in liver cancer. " 04/01/2014 - "In the present study, the anticancer efficacy of a novel escheriosome-based formulation of PLK1-specific siRNA was evaluated against liver cancer in BALB/c mice. " 04/01/2014 - "Our data demonstrate the efficacy of systemically administered siRNA in the treatment of experimental liver cancer. " 08/01/2015 - "In the present study, HepG2 liver cancer cells were transfected with small interfering RNA (siRNA) against β-catenin and STAT3 alone or in combination. " 10/01/2007 - "To study the role of inhibition FAK expression by FAK siRNA in liver cancer cell (MHCC97-H) adhesion, invasion and cytoskeleton rearrangement. "
5.	AflatoxinsIBA 09/01/2006 - "With improved accuracy and precision, this sensitive biomarker for recent human exposure to AFB(1) will be especially useful for measuring the efficacy of planned interventions to reduce aflatoxin-related liver cancer in AFB(1)-exposed populations." 01/01/2012 - "The main exception is for aflatoxins; epidemiological, experimental, and mechanistic studies have contributed to establishing aflatoxins as a cause of human liver cancer, with a particularly elevated risk in people chronically infected with hepatitis B virus. " 03/01/1992 - "Risk modeling is used to assess the dose-response relationship between aflatoxin exposure and primary liver cancer, controlling for hepatitis B virus (HBV), based on data provided by the Yeh et al. study in China. " 09/01/1991 - " There is good experimental evidence that aflatoxin acts as an initiator for liver cancer, but there is not practical way to judge exposure for clinical studies." 12/01/1990 - "A review of epidemiology literature revealed that only studies conducted in Africa and Asia included data adequate to permit quantitative assessment of the dose-response relationship between aflatoxin exposure levels and liver cancer rates. "
6.	alpha-Fetoproteins (AFP)IBA 05/01/1988 - "The determination of AFP variant is helpful in early detection of small liver cancer." 09/15/2015 - "Our previous studies indicated that targeted expression of therapeutic BikDD driven by a liver cancer-specific α-fetoprotein promoter/enhancer (eAFP) in the VISA backbone (eAFP-VISA-BikDD) significantly and specifically kills HCC cells in multiple orthotopic animal models. " 01/01/2014 - "The aim of this study is to elucidate the effectiveness and complications of fine needle aspiration in a Chinese population with primary liver cancer and AFP levels ≤200 ng/ml. A retrospective study was conducted over a period of 28 years. " 01/01/2014 - "Effectiveness and complications of ultrasound guided fine needle aspiration for primary liver cancer in a Chinese population with serum α-fetoprotein levels ≤200 ng/ml--a study based on 4,312 patients." 04/14/2011 - "In the current study, we developed a promising HCC-targeted gene therapy vector driven by liver cancer-specific α-fetoprotein promoter/enhancer coupled to an established platform technology. "
7.	Ethanol (Ethyl Alcohol)IBA 06/01/2013 - "Ethanol ablation (EA) is a safe and effective method for treating small liver cancer. " 03/31/2009 - "[Meta-analysis of the efficacy of transcatheter arterial chemoembolization combined with percutaneous ethanol injection in treating unresectable primary liver cancer]." 01/01/2014 - "The purpose of this study was to confirm the anticancer activity of an ethanol extract of Saussurea involucrata against hepatic cancer and elucidate its mechanisms of action. " 08/01/2010 - "The aim of this study was to test whether long-term ethanol consumption confers therapeutic resistance to human liver cancer patients infected with hepatitis B virus (HBV). " 03/31/2009 - "All randomized controlled trials comparing transcatheter arterial chemoembolization alone with transcatheter arterial chemoembolization combined with percutaneous ethanol injection for treating unresectable primary liver cancer were identified and screened by two reviewers, and the methodological quality of the included randomized controlled trials were evaluated by Jadad scale. "
8.	AntigensIBA 12/01/2008 - "The improved antigen binding of SLH10 BsFv may be useful for immunodiagnostics or targeted gene therapy for liver cancer." 01/01/2010 - "Some reports also indicate similar association in humans, where the presence of Helicobacter antigens in patients with liver cancer is detected more often in comparison to healthy or chronically infected population. " 10/01/2008 - "RhGM-CSF and rhIL-4 were administered to induce the monocytes differentiation into DCs, and then loaded with different antigens (lysate antigen of autologous liver cancer cells and cell line SMMC-7721 cells). " 01/01/2004 - "[Evaluation of a risk of a cross-reactivity with Echinococcus multilocularis-specific Em2plus antigen in patients with liver cancer]." 01/01/2001 - "The hepatitis B virus-encoded X antigen (HBxAg) may contribute to the development of liver cancer, in part, by stimulating the growth and survival of infected cells in the face of ongoing immune responses. "
9.	Biological Markers (Surrogate Marker)IBA 10/01/2013 - "As liver cancer is often asymptomatic, the development of sensitive noninvasive biomarkers is needed for early detection and improved survival. " 06/04/2010 - "Combination of improved (18)O incorporation and multiple reaction monitoring: a universal strategy for absolute quantitative verification of serum candidate biomarkers of liver cancer." 01/01/2014 - "In this study, we used liver cancer as the target and developed a text-mining-based curation system named LiverCancerMarkerRIF, which allows users to retrieve biomarker-related narrations and curators to curate supporting evidence on liver cancer biomarkers directly while browsing PubMed. " 11/07/2013 - "To evaluate the performance of different normalization methods, we consider LC-MS data from a study where metabolomic approach is utilized to discover biomarkers for liver cancer. " 12/01/2009 - "In this review, I have summarized my presentation at the recent HCC workshop at IARC, Lyon, on our knowledge generated from comprehensive molecular studies of primary liver cancer tissues and attempt to translate these results to gain molecular insights, especially on identification of biomarkers that could confer pathological and functional changes associated with the pathogenesis and progression of HCC, hoping to provide important molecular basis for the development of novel diagnosis and treatments to alter clinical outcomes of this disease."
10.	Liposomes (Liposome)IBA 06/26/2013 - "These findings support the fact that FVS, a potential nutraceutical and an effective drug for the treatment of liver cancer, could be encapsulated in liposomes for improved solubility and bioavailability. " 04/01/2002 - "SEA liposomes possess liver-targeting properties and may provide a new application foreground for the treatment of liver cancer." 07/01/1998 - "The antitumor activity of SG-liposomes in rats with primary liver cancer was significantly higher compared with free DOX and non-SG-liposomes (ILS: 92.7%)." 05/18/2015 - "Thus surface modified liposomes specific to target heptocytes demonstrate a promising approach for targeted drug delivery in liver cancer therapeutics." 04/01/2011 - "Anti-tumor activity of SPC, HSPC and novel stealth liposomes composed of both SPC and HSPC were compared by established mouse liver cancer H22 model. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 06/01/2014 - "Multidrug resistance (MDR) is one of the major reasons for the failure of liver cancer chemotherapy, and its suppression may increase the efficacy of chemotherapy. " 05/01/2002 - "Standard chemotherapy approaches for hepatic neoplasms are effective in only 20-30% of cases. " 02/01/1991 - "These results show that combined use of DSM is effective for intra-arterial chemotherapy against metastatic hepatic cancer." 08/01/1989 - "These results show that combined use of DSM is effective for intra-arterial chemotherapy against the hepatic cancer." 01/01/2000 - "The assessment of ER and DR using 99mTc-MIBI intraarterial SPECT is considered to be useful for prediction of the clinical efficacy of hepatic arterial chemotherapy for metastatic hepatic cancer."
2.	Hepatectomy 04/01/2011 - "This study demonstrated a significant improvement in QOL after hepatectomy for liver neoplasm in the AEN group based on the same patients' preoperative SF-36 scores (P < 0.05). " 11/01/2004 - "Although hepatectomy has been widely accepted as treatment of choice to offer a chance of cure for patients with liver cancer, little is known about the subjective clinical results after this operation. " 08/01/2015 - "To study the clinical efficacy of three dimensional visualization technique assisted hepatectomy for the treatment of primary liver cancer. " 08/01/2015 - "[Efficacy of three dimensional visualization technique assisted hepatectomy for the treatment of primary liver cancer]." 11/21/2006 - "Clinical and pathological features of both primary and metastatic liver cancers were entered into a multivariate analysis to determine independent variables helpful in accurately predicting long-term prognosis after hepatectomy. "
3.	Liver Transplantation 01/01/1993 - "Resectional surgery remains the best treatment for primary liver cancer and, in selected cases, liver transplantation is worthwhile. " 10/01/2015 - "Marked improvement in the prognosis for patients with liver cancer who undergo liver transplantation has been achieved as a result of advances in liver transplantation techniques. " 01/01/2000 - "New data show that perioperative cytostatic therapy is beneficial in the case of liver transplantation for hepatic cancer. " 06/26/2006 - "Effective treatment for liver cancer includes surgical resection, liver transplantation and percutaneous ablation. " 09/01/2012 - "In the present study, we evaluated the expression of MALAT1 by quantitative real-time PCR in 9 liver cancer cell lines and 112 HCC cases including 60 cases who received liver transplantation (LT) with complete follow-up data. "
4.	Immunotherapy 04/20/2015 - "Immunotherapy is a promising treatment for liver cancer. " 04/01/2013 - "Immunotherapy: Oncolytic vaccinia virus shows promise in liver cancer." 10/15/2004 - "These results show the efficacy of peptide immunotherapy in the treatment of liver cancer." 09/01/2002 - "Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer." 10/01/2015 - "Finally, we present the current achievements in NK cell immunotherapy conducted in mouse models of liver cancer and in clinical trials, highlighting how chemoimmunotherapy, NK cell transfer, gene therapy, cytokine therapy and mAb therapy improve NK cell function in HCC treatment. "
5.	Radiotherapy 11/10/2015 - "These data show that direct SGK1 inhibition can be effective in hepatic cancer therapy, either alone or in combination with radiotherapy. " 12/01/2007 - "Such SPION might be very useful for bio-magnetically targeted radiotherapy in liver cancer treatment." 11/01/2013 - "[Efficacy of stereotactic radiotherapy for primary and metastatic liver cancer]." 02/01/2012 - "Improved radiotherapy for primary and secondary liver cancer: stereotactic body radiation therapy." 01/01/2014 - "The aim of this preclinical study was to evaluate the expression of PARP and PARG genes in a panel of liver cancer cell lines and primary human hepatocytes, their DNA repair capacity and assess the impact on cell survival of PARP inhibitors alone and in combination with radiotherapy. "